We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 1,019

Federal Court grants prohibition order with respect to a use patent
  • Borden Ladner Gervais LLP
  • Canada
  • July 29 2015

The Federal Court considered and dismissed allegations relating to double patenting, insufficiency and lack of standing. The Court granted the


FCA finds patent should be listed on the patent register for combination drug
  • Borden Ladner Gervais LLP
  • Canada
  • July 29 2015

In this case, the FCA overturned the Federal Court Decision dismissing Eli Lilly’s application for judicial review of a decision of the Minister of


Pharma in brief - Federal Court of Appeal relaxes the “perfect match” requirement for patent listing under the Patented Medicines (Notice of Compliance) Regulations
  • Norton Rose Fulbright Canada LLP
  • Canada
  • July 28 2015

The Minister of Health refused to list a patent on the Patent Register in respect of a fixed-dose combination product because it did not contain a


Pharma in brief - Federal Court of Appeal finds that “promised” utility need not be coterminous with the inventive concept
  • Norton Rose Fulbright Canada LLP
  • Canada
  • July 27 2015

AstraZeneca Canada Inc. (AstraZeneca) appealed from the decision of Justice Rennie of the Federal Court (reported as AstraZeneca Canada Inc. v


Federal Court of Appeal reinterprets product specificity requirements: patent listing is determined by patent claims construction and not a word match
  • Gowling Lafleur Henderson LLP
  • Canada
  • July 23 2015

On July 17, 2015, the Federal Court of Appeal set aside a judgment of the Federal Court that upheld Health Canada’s refusal to list Canadian Patent 2


Mayo on the side? The Canadian Patent Office issues new examination guidelines for medical diagnostic methods
  • Borden Ladner Gervais LLP
  • Canada
  • July 17 2015

On June 29, 2015, the Canadian Intellectual Property Office (CIPO) issued a long-awaited Practice Notice PN 2015-02("Notice") on the subject of


Court of Appeal gives guidance on sound prediction issues
  • Borden Ladner Gervais LLP
  • Canada
  • July 15 2015

The Federal Court of Appeal (FCA) upheld a recent infringement decision finding a patent to be invalid due to inutility (decision here; summary here


Innovator delays its own Canadian drug approval in effort to secure data protection
  • McCarthy Tétrault LLP
  • Canada
  • July 10 2015

On June 12, 2015, at the urgent request of Horizon Pharma PLC (“Horizon”), the Federal Court of Canada granted a rare interlocutory stay preventing


Federal court grants accounting of profits and addresses NIA “non-infringing alternative”
  • Gowling Lafleur Henderson LLP
  • Canada
  • July 10 2015

The Federal Court recently released a decision Accounting for an infringer's profits in a pharmaceutical matter (ADIR and Servier Canada Inc. v


FCA does not address trial judge’s finding that there is no heightened disclosure requirement in cases of sound prediction
  • Gowling Lafleur Henderson LLP
  • Canada
  • July 10 2015

The FCA has released its reasons in the appeal of Justice Rennie’s Esomeprazole decision. In Esomeprazole, Rennie J. Found AstraZeneca’s patent to be